Lupus erythematosus profundus (lupus panniculitis) induced by interferon-beta in a multiple sclerosis patient.
We report a patient with multiple sclerosis (MS) who developed subcutaneous nodules on the face, shoulders and extremities while being treated with interferon (IFN)-beta-1b. These nodules fluctuated in parallel with myelopathy, and were diagnosed as lupus erythematosus profundus (LEP) based on histopathological findings. The patient showed no relapse of either neurological symptoms or subcutaneous nodules after cessation of IFN-beta-1b. This agent can cause induration and necrosis in the sites of injection but also systemic skin lesions such as LEP ascribable to its immunomodulatory effects.
Gono
Takahisa
T
Department of Internal Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
Matsuda
Masayuki
M
Shimojima
Yasuhiro
Y
Kaneko
Kazuma
K
Murata
Hiroshi
H
Ikeda
Shu-ichi
S
D000328:Adult; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D015435:Panniculitis, Lupus Erythematosus / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D050151:Subcutaneous Fat / Q000187:drug effects* / Q000276:immunology / Q000473:pathology*; D028761:Withholding Treatment
D007155:Immunologic Factors; D000068576:Interferon beta-1b; D016899:Interferon-beta